Up to €1,300 savings end in:
- 00Days
- 00Hrs
- 00Mins
- 00Secs
March 23–25, 2026
FIL (Feira Internacional de Lisboa), Lisbon, PortugalMarch 31 – April 1, 2026 | Digital Partnering Magdalena TyrpienCo-Founder & CEO at Nionyx BioSpeaker
Profile
Magdalena Tyrpien is the Co-Founder and CEO of Nionyx Bio, a New York-based biotech developing next-generation AAV gene therapies for kidney disease. Previously Chief Business Officer at Forge Biologics, she led its $620 M acquisition by Ajinomoto. Magdalena has built and financed multiple gene therapy companies and now leads Nionyx in advancing safe, one-time treatments for renal disorders.